Activation of the MET pathway has been known to ameliorate alcoholic steatohepatitis and liver fibrosis or cirrhosis in pre-clinical models of liver disease (Matsuda et al, 1995;, Matsuda, 1997;, Tahara et al, 1999;, Taïeb et al, 2002), and conversely, deletion of the MET gene in postnatal mice causes hyperlipidemia, severe steatosis, and progressive liver disease (Kroy et al, 2014). This evidence concerns the gene MET and hyperlipidemia.